USA — Abbott Laboratories has received FDA approval for its Eterna spinal cord stimulation (SCS) system for chronic pain management.

The Eterna SCS system is the smallest implantable, rechargeable system currently available for this indication on the market.

The recent development is expected to strengthen Abbott’s Established Pharmaceuticals Division (EPD).

It also stated that the Eterna SCS system was created after extensive research with patients, physicians, and caregivers to better understand the unmet needs of chronic pain patients.

According to the company, SCS technology reduces pain by 23% more than traditional waveform technology approaches.

To provide superior pain relief, Eterna SCS employs the company’s proprietary low-dose BurstDR stimulation, which mimics natural firing patterns in the brain.

Notably, Eterna improves the patient charging experience by requiring as few as five recharges per year when used in conjunction with a wireless charger.

Furthermore, Eterna employs Abbott’s TotalScan MRI technology, which allows for full-body MRI scans — a critical need for chronic pain patients who require access to advanced diagnostics and healthcare.

The importance of approval

It is worth noting that over 50 million people in the United States suffer from chronic pain. According to the United States Pain Foundation, chronic pain is the leading cause of doctor visits and costs the country US$635 billion per year in healthcare, disability, and lost productivity costs.

Abbott’s low-dose BurstDR stimulation has been clinically proven to reduce pain, improve people’s ability to perform daily tasks, and reduce emotional suffering associated with pain.

According to Grand View Research, the global spinal cord stimulation devices market was worth US$1.83 billion in 2018 and is expected to grow at an 8.7% CAGR by 2026.

The growing number of patients suffering from failed back syndrome, chronic pain, and Complex Regional Pain Syndrome (CRPS) is driving the market.

In other recent developments, Abbott Established Pharmaceuticals sales increased 4.9% on a reported basis (up 12.2% on an organic basis) to US$1.33 billion in the third quarter of 2023. Year on year, organic sales in key emerging markets increased by 13%.

According to Abbott, organic sales growth was supported by strong growth in several geographies, including India, China, Brazil, and Vietnam, as well as several therapeutic areas, including cardiometabolic, gastroenterology, and pain management.

Abbott also stated in its most recent earnings update that EPD has achieved double-digit organic sales growth since the beginning of 2021, owing to a consistent cadence of new product launches and strong commercial execution.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.